Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Information source: Celgene Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Adriamycin and Cytoxan (AC) (Drug); ABI-007 (Drug); Taxol (Drug); Bevacizumab (Drug); pegfilgrastim (Drug)
Phase: Phase 2
Sponsored by: Celgene Corporation
The primary objective of this study was to compare the safety of dose-dense ABI-007
(Abraxane) 260 mg/m^2 or Taxol 175 mg/m^2 given every 2 weeks following dose-dense
Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2
weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Official title: An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy
The Cumulative Dose of Taxane Delivered During Study
Mean Taxane Dose Intensity Per Week
Percent of Protocol Taxane Dose
Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays
Myelosuppression During Taxane Dosing Cycles
Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation
Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)
Minimum age: 18 Years.
Maximum age: 70 Years.
A patient was eligible for inclusion in this study only if all of the following criteria
1. Female, age greater than or equal to 18 to less than or equal to 70 years old.
2. Estrogen receptor (ER) and progesterone receptor (PR) status have been determined.
3. Operable, histologically confirmed adenocarcinoma of the breast
4. Must have met 1 of the following criteria:
- T1-3, N1-3, M0, regardless of ER or PR status.
- T > 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.
- T > 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative
- T > 1 cm, N0, M0, ER or PR positive and grade 3
5. Patients with one sentinel lymph node metastasis 0. 2-2 mm in size were not required
to undergo completion axillary dissection unless only 1 sentinel lymph node was
examined. This completion axillary dissection was optional if 1 out of 2 or more
sentinel lymph nodes was positive for a micrometastasis. Therefore if 1 of 1
sentinel lymph node was positive for micrometastasis(0. 2-2 mm), then a completion
axillary dissection was required.
6. Patients with more than one sentinel node micrometastasis or 1 node with a
micrometastasis > 2 mm and/or T3 disease must have undergone completion, standard
axillary dissection. - Note: the following were not eligible-
T1b,c,N0M0 and ER or PR positive and grade 1 or 2 Tx tumors (regardless of nodal
status) T4 disease [i. e., patients with fixed tumors, peau d'orange skin changes,
skin ulcerations, or inflammatory changes
- Note: Sentinel lymph node micrometastasis < 0. 2 mm in considered N0 disease
7. Negative surgical margins on lumpectomy or mastectomy specimen (no ink on invasive
cancer and no ink on ductal carcinoma in situ [DCIS]).
8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
9. Normal electrocardiogram (ECG, as assessed by the investigator).
10. No pre-existing peripheral neuropathy.
11. It had not been longer than 84 days since the date of definitive surgery (eg,
mastectomy or in the case of a breast-sparing procedure, axillary dissection).
12. Laboratory values were to be as follows:
- White blood cell count: > or equal to 3,000/mm^3
- Absolute neutrophil count:> or equal to 1,500/mm^3
- Platelets:> or equal to 100,000/mm^3
- Hemoglobin: > or equal to 8g/dL
- Bilirubin:< or equal to the institution's ULN
- Creatinine: < or equal to 1. 7 mg/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline
phosphatase could be up to 2. 5 times the institutional ULN.
13. All staging studies including physical exam, chest x-ray, and bone scan had to show
no evidence of metastatic disease, including suspicious lymphadenopathy or skin
nodules on physical exam. A chest x-ray and bone scan were mandatory; however, all
other staging studies were at the treating physician's discretion. Any other staging
test (eg, Computed Tomography [CT] scans, magnetic resonance imaging [MRI] studies,
ultrasound of abdomen, Positron Emission Tomography [PET] scans must have been
negative for metastatic disease. An abdominal CT scan or PET scan was mandatory for
patients with liver function tests elevated above the upper limit of normal (ULN) to
rule out metastatic disease. If the patient had a staging PET scan then a bone scan
was not necessary, but a chest x-ray was required.
14. Patient had a negative serum pregnancy test < or equal to 14 days of the first dose
of study drug (patients of childbearing potential).
15. If fertile, patient had agreed to us an acceptable method of birth control to avoid
pregnancy [Note: oral contraceptives were not allowed] for the duration of
chemotherapy and hormonal therapy and for 6 months thereafter.
16. If obese, a patient must have been treated with doses calculated using his/her actual
body surface area (BSA) (the physician must have been comfortable treating at the
full BSA dose regardless of BSA).
17. Patient had signed a Patient Informed Consent Form.
A patient was not eligible for inclusion in this study if any of the following criteria
1. Patients with HER-2 positive breast cancer (IHC 3+ or FISH +) who were eligible for
adjuvant Herceptin therapy.
2. Stage IV breast cancer (M1 disease on TNM staging system).
3. Prior anthracycline, anthracenedione (mitoxantrone), or taxane therapy
4. Neoadjuvant therapy for this breast cancer.
5. Previous invasive cancers if treated < 5 years prior to entering this study, except
basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; the
latter were not required to have occurred more than 5 years prior to study entry.
6. Prior invasive breast cancer if diagnosed < 5 years prior to entering study.
Patients must have finished adjuvant hormonal therapy prior to registration.
Patients with prior DCIS are eligible. Patients with DCIS who were treated with
tamoxifen must have finished tamoxifen prior to registration.
7. Serious medical illness, other than that treated by this study, which would limit
survival to < 4 years, or psychiatric condition that would prevent informed consent
and compliance with study treatment.
8. Uncontrolled or severe cardiovascular disease including recent (< or equal to 12
months) myocardial infarction or unstable angina.
9. Active uncontrolled bacterial, viral (including clinically defined Acquired Immune
Deficiency Syndrome [AIDS]), or fungal infection.
10. Patients with active or chronic hepatitis with abnormal liver function tests (LFTs)
or patients who were known to be HIV positive.
11. Uncontrolled disease such as uncontrolled diabetes.
12. Any prior history of hypertensive crisis or hypertensive encephalopathy.
13. Any known central nervous system (CNS) disease.
14. Known hypersensitivity to any component of bevacizumab.
15. No history of cerebrovascular accident or transient ischemic attack at any time.
16. Active symptomatic vascular disease, e. g., aortic aneurysm or aortic dissection, and
no peripheral vascular disease, e. g., claudication, within six months of study entry.
17. No major surgical procedure, open biopsy, or significant traumatic injury within 28
days and no core biopsy or minor surgical procedure (excluding placement of a
vascular access device) within seven days of study entry. No anticipated need for
major surgical procedure during the course of study.
18. No history of abdominal fistula, gastrointestinal perforation, or intra- abdominal
process within six months of study entry.
19. No serious non-healing wound, ulcer, or bone fracture.
20. No proteinuria at screening as demonstrated by urine protein: urine creatinine (UPC)
ratio of > or equal to 1. 0 or urine dipstick for proteinuria > or equal to 2+
(patients discovered to have > or equal to 2+ proteinuria on dipstick urinalysis at
baseline should have undergone a 24 hour urine collection and must have demonstrated
< or equal to 1g of protein in 24 hours to be eligible).
21. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg
and /or diastolic blood pressure> 100 mmHg on antihypertensive medications) or New
York Heart Association (NYHA) Grade 2 or greater congestive heart failure.
22. History or coagulopathy, bleeding diathesis, therapeutic anticoagulation other than
low dose or chronic acetyl salicylic acid (ASA)> or equal to 325 mg. per day. Low
dose coumadin for anticoagulation of venous access device or low dose molecular
weight heparin (LMWH) for deep vein thrombosis prophylaxis or low dose (325 mg or
less) ASA prophylaxis are allowed, but are best avoided if the treating physician
feels it is safe to do so.
23. Left Ventricular Ejection Fraction (LVEF) on cardiac echocardiography (ECHO) < 50%
(or institutional lower limit of normal [LLN]) and > or equal to 74%. LVEF of greater
than 75% at baseline should have been re- reviewed and/or the test repeated as it
could be falsely elevated.
24. Patients who were receiving concurrent immunotherapy.
25. A history of other malignancy within the last 5 years, which could affect the
diagnosis or assessment of breast cancer recurrence or which could shorten a
26. Patient had had an organ allograft.
27. Patient was pregnant or breastfeeding.
28. Patient was unable to comply with requirements of study.
29. Patient was receiving any other investigational drugs.
Locations and Contacts
Birmingham, Alabama 35205, United States
Sedona, Arizona 86336, United States
Denver, Colorado 80220, United States
Torrington, Connecticut 06790, United States
Indianapolis, Indiana 46227, United States
Minneapolis, Minnesota 55404, United States
Columbia, Missouri 65201, United States
St. Louis, Missouri 63136, United States
Henderson, Nevada 89052, United States
Raleigh, North Carolina 27607, United States
Eugene, Oregon 97401, United States
Greenville, South Carolina 29615, United States
Austin, Texas 78731, United States
Bedford, Texas 76022, United States
Dallas, Texas 75231, United States
Dallas, Texas 75246, United States
El Paso, Texas 79915, United States
Fort Worth, Texas 76104, United States
Fredericksburg, Texas 78624, United States
Houston, Texas 77024, United States
Longview, Texas 75601, United States
McAllen, Texas 78503, United States
Tyler, Texas 75702, United States
Waco, Texas 76712, United States
Fairfax, Virginia 22031, United States
Norfolk, Virginia 23502, United States
Vancouver, Washington 98684, United States
Starting date: August 2006
Last updated: August 8, 2013